Nanoparticle systems (NP) can be used to deliver diagnostics and therapeutics including small and large molecules, gene vectors, and biosensor. As NP is versatile and can be made of different types of materials, and can have different sizes, surface charges, and surface modifications, there is the potential to tailor the design of NP for its intended function. Such goals can be greatly facilitated by quantitative models that predict the NP delivery to target sites and the biointerfaces (e.g., NP disposition and interactions with targets). In general, tumor properties, biological in nature, are dynamic and altered by a variety of variables and can produce diverse and at times unexpected effects on NP disposition. These situations in turn create uncertainties on the fate of NP at target sites and hence questions on the NP design. For example, how should one design NP in anticipation of intratumoral heterogeneity in the transport mechanisms (diffusion vs convection) in different parts of a tumor, or treatment-induced changes in tumor vasculature or properties? What are the margins of error if the NP design/selection does not take into account the diverse/dynamic tumor properties? Similarly, some NP properties by design will produce uncertain or opposite outcomes. For example, NP is frequently surface-modified with targeting ligands, but binding of ligands to cell surface receptors limits NP transport. What are the binding characteristics that would yield an optimal balance between tumor selectivity and tumor penetration? Pegylation increases circulation times but also decreases the endocytosis of NP. What is the range of % pegylation to enable optimal tumor targeting? We propose that the above and similar questions can be addressed by developing computation models that use relatively few in vitro and in vivo experimental data to describe the extravasation, interstitial deposition and transport, and internalization of NP in solid tumors as functions of NP/tumor properties and biointerfaces, and treatment schedules (dose intensity and frequency). We will take a balanced empirical-theoretical approach that uses our combined expertise in pharmacokinetics, drug/NP delivery, modeling, simulations, tumor heterogeneity, and in vitro and in vivo experimentations. The model parameters are either lab-generated, obtained from the literature, calculated using well-known equations, or, in the case of parameters that cannot be measured, by fitting the data to equations. Model performance is evaluated by conducting experiments and comparing the lab-generated data to the model-predicted data. We have developed first-generation models that successfully used in vitro data of drug/NP-cell-protein interactions in 2-D monolayers to predict the in vivo transport/delivery of a small molecule drug and NP to tumors. We further used these models, together with in vivo measurements of vessel density and diameter, to simulate the effect of chemotherapy, as well as the effects of intra-tumoral heterogeneity. This project is expected to contribute to NP design principles and accelerate the development of cancer nanotechnology.
Nanoparticle systems (NP) can be used to deliver diagnostics and therapeutics including small and large molecules, gene vectors, and biosensor. As NP is versatile and can be made of different types of materials, and can have different sizes, surface charges, and surface modifications, there is the potential to tailor the design of NP for its intended function. The fate and utility of NP depend on the NP interactions with biological materials. We propose to capture the dynamic and inter- dependent biointerfaces in nanotechanology design principles by developing multi-scale computational models to describe the fate of NP at target sites as mathematical functions of NP/tumor properties and biointerfaces.
|Jaiprasart, Pharavee; Yeung, Bertrand Z; Lu, Ze et al. (2018) Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex. J Control Release 270:101-113|
|Wang, Jin; Yeung, Bertrand Z; Cui, Minjian et al. (2017) Exosome is a mechanism of intercellular drug transfer: Application of quantitative pharmacology. J Control Release 268:147-158|
|Au, Jessie L-S; Yeung, Bertrand Z; Wientjes, Michael G et al. (2016) Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities. Adv Drug Deliv Rev 97:280-301|
|Au, Jessie L-S; Lu, Ze; Wientjes, M Guillaume (2015) Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer. AAPS J 17:1065-79|
|Wientjes, Michael G; Yeung, Bertrand Z; Lu, Ze et al. (2014) Predicting diffusive transport of cationic liposomes in 3-dimensional tumor spheroids. J Control Release 192:10-8|
|Au, Jessie L-S; Guo, Peng; Gao, Yue et al. (2014) Multiscale tumor spatiokinetic model for intraperitoneal therapy. AAPS J 16:424-39|
|Wang, Jie; Lu, Ze; Yeung, Bertrand Z et al. (2014) Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors. J Control Release 178:79-85|
|Tsai, Max; Lu, Ze; Wientjes, M Guillaume et al. (2013) Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics. J Control Release 172:737-44|
|Gao, Yue; Li, Mingguang; Chen, Bin et al. (2013) Predictive models of diffusive nanoparticle transport in 3-dimensional tumor cell spheroids. AAPS J 15:816-31|
|Li, Yinghuan; Wang, Jie; Gao, Yue et al. (2011) Relationships between liposome properties, cell membrane binding, intracellular processing, and intracellular bioavailability. AAPS J 13:585-97|
Showing the most recent 10 out of 11 publications